Form 4 Filing for Aquestive Therapeutics, Inc. - Officer Stock Acquisition

Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc., acquired 60,000 Performance Stock Units (PSUs) on March 7, 2025. These PSUs have a grant date of March 7, 2025, and an expiration date of March 7, 2028. The PSUs measure performance over a three-year period and vest 100% on March 7, 2028, if earned. Each PSU represents a contingent right to receive one share of the Company's common stock. The performance price is determined by the 30-day average Nasdaq closing price during specific periods. This Form 4 filing was submitted late due to an inadvertent administrative oversight. The reported post-transaction shares owned by Ms. Jung are 60,000.